Literature DB >> 16868945

Clinical reactivation after liver transplantation with an unusual minor strain of hepatitis B virus in an occult carrier.

Bernhard Zöllner1, Heinz-Hubert Feucht, Martina Sterneck, Hansjörg Schäfer, Xavier Rogiers, Lutz Fischer.   

Abstract

Hepatitis B virus (HBV) DNA is detectable in a number of liver transplant candidates who are negative for hepatitis B surface antigen (HBsAg). After liver transplantation (LT), such patients may have molecular and/or serologic evidence of HBV replication. However, clinical disease from reactivation of occult HBV infection after LT has not been described. We report a patient who underwent LT for cryptogenic cirrhosis and had to be retransplanted twice for hepatic artery thrombosis. The patient was negative for HBsAg and positive for anti-hepatitis B core (HBc) and anti-HBs before all LT procedures and developed acute hepatitis B shortly after receiving the third graft. The HBV strain isolated at that time exhibited an unusual in frame insertion of a CAG motif within the HBV polymerase (HBV(INS+)). HBV(INS+) was detected retrospectively as a minor species in pretransplantation sera and the explanted native liver by insertion-specific polymerase chain reaction. This case in an occult HBV carrier shows that clinically apparent, endogenous reinfection of the graft may occur with minor HBV variants that are not detectable in pretransplantation samples by standard diagnostic procedures. This has implications for the analysis of sources of acute hepatitis B in patients after LT and possibly for consideration of antiviral prophylaxis in anti-HBc/anti-HBs/HBV DNA-positive patients. (c) 2006 AASLD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868945     DOI: 10.1002/lt.20858

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  5 in total

1.  The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients.

Authors:  Zhaoshi Jiang; Suchit Jhunjhunwala; Jinfeng Liu; Peter M Haverty; Michael I Kennemer; Yinghui Guan; William Lee; Paolo Carnevali; Jeremy Stinson; Stephanie Johnson; Jingyu Diao; Stacy Yeung; Adrian Jubb; Weilan Ye; Thomas D Wu; Sharookh B Kapadia; Frederic J de Sauvage; Robert C Gentleman; Howard M Stern; Somasekar Seshagiri; Krishna P Pant; Zora Modrusan; Dennis G Ballinger; Zemin Zhang
Journal:  Genome Res       Date:  2012-01-20       Impact factor: 9.043

Review 2.  Management of occult hepatitis B virus infection: an update for the clinician.

Authors:  José Luis Lledó; Conrado Fernández; María Luisa Gutiérrez; Sara Ocaña
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

3.  Post-transfusion occult hepatitis B (OBI): a global challenge for blood recipients and health authorities.

Authors:  Mohammad Kazemi Arababadi; Gholamhossein Hassanshahi; Ali Akbar Pourfathollah; Ebrahim Rezazadeh Zarandi; Derek Kennedy
Journal:  Hepat Mon       Date:  2011-09       Impact factor: 0.660

Review 4.  Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management.

Authors:  Ranjit Chauhan; Shilpa Lingala; Chiranjeevi Gadiparthi; Nivedita Lahiri; Smruti R Mohanty; Jian Wu; Tomasz I Michalak; Sanjaya K Satapathy
Journal:  World J Hepatol       Date:  2018-03-27

5.  Synergistic impact of mutations in Hepatitis B Virus genome contribute to its occult phenotype in chronic Hepatitis C Virus carriers.

Authors:  Rajiv Kumar Mondal; Mousumi Khatun; Priyanka Banerjee; Alip Ghosh; Sumanta Sarkar; Amal Santra; Kausik Das; Abhijit Chowdhury; Soma Banerjee; Simanti Datta
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.